<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article107</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index_gpt.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/ADVOR" style="display:block; margin-bottom:10px;">ADVOR Original</a></li>
<h2><strong>ADVOR</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Acetazolamide in Patients with Acute Decompensated Heart Failure with Volume Overload".The New England Journal of Medicine. 2023.<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
Does the addition of acetazolamide to loop diuretic therapy in patients with acute decompensated heart failure result in improved decongestion?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
Adding acetazolamide to loop diuretic therapy in acute decompensated heart failure patients with volume overload led to a more successful decongestion within 3 days of treatment, as well as a more pronounced reduction in congestion symptoms, with similar safety profiles observed between acetazolamide and placebo groups.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
Current guidelines recommend intravenous loop diuretics for symptom relief from fluid overload in patients with acute decompensated heart failure; however, there is limited evidence on effective adjunctive diuretic therapy.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
- Multicenter, parallel-group, double-blind, randomized, placebo-controlled trial<br/>
- N=519 patients with acute decompensated heart failure<br/>
- Acetazolamide 500mg IV once daily (n=259)<br/>
- Placebo (n=260)<br/>
- Setting: 27 centers in Belgium<br/>
- Enrollment: 2018-2022<br/>
- Follow-up: 3 months<br/>
- Analysis: Intention-to-treat<br/>
- Primary outcome: Successful decongestion within 3 days of treatment<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
- Inclusion Criteria: Adults with acute decompensated heart failure and signs of volume overload (edema, pleural effusion, or ascites), NT-proBNP &gt;1000 pg/ml or BNP &gt;250 pg/ml, prior loop diuretic maintenance for â‰¥1 month<br/>
- Exclusion Criteria: Use of acetazolamide or another proximal tubular diuretic (e.g. SGLT2 inhibitors), systolic BP &lt;90 mm Hg, estimated GFR &lt;20 ml/min/1.73 m^2, IV loop diuretics &gt;80 mg furosemide equivalent prior to randomization<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- Acetazolamide 500 mg IV or placebo added to standardized IV loop diuretics (dose equivalent to twice the oral maintenance dose) once daily<br/>
- Oral loop diuretics were discontinued during the trial period<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
- Primary: Successful decongestion within 3 days of randomization without escalation of decongestive therapy<br/>
- Secondary: Composite of death from any cause or rehospitalization for heart failure during 3 months<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
- Majority of trial participants were White, limiting generalizability to other racial or ethnic groups.<br/>
- The study population had chronic heart failure history and were on outpatient treatment with loop diuretics, which may not apply to newly diagnosed heart failure patients.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
The trial was funded by the Belgian Health Care Knowledge Center.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/><p></p>
</div>
</div>
</div>
</div>
</body>
</html>
